[Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
This article reviews the current evidence of effects on cardiovascular disease (CVD) of anti-diabetic treatment which exert their effect by increasing the insulin sensitivity in patients with type 2 diabetes (T2D). In overweight T2D patients, it has been demonstrated that metformin reduces the CVD risk. The effect of glitazones on CVD is uncertain. There is insufficient evidence to support a protective effect on CVD of lowering blood-glucose per se. In contrast, lowering blood glucose appears to decrease the risk of microvascular complications.
Hemmingsen
Bianca
B
Steno Diabetes Center, Gentofte. biancahemmingsen@hotmail.com
Lund
Søren S
SS
Vaag
Allan
A
D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000209:etiology / Q000517:prevention & control; D004338:Drug Combinations; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D008687:Metformin / Q000627:therapeutic use*; D012307:Risk Factors; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000627:therapeutic use*
D004338:Drug Combinations; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; D008687:Metformin